An article published this year in “PLOS ONE” using our
Anti-CD3 CF-Blue™ (clone UCHT-1), by our customers from Immunology Service,
University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, Tissue
Typing Laboratory, University Hospital Marqués de Valdecilla, Santander, Spain,
in the Improvement in the definition of anti-HLA antibody profile in highly
sensitized patients. Congrats and Thanks.
Summary:
The definition of anti-HLA
antibody profile in highly sensitized patients on a waiting list is crucial
when virtual crossmatch is used in organ allocation systems, but also when used
to identify the true deleterious anti-HLA antibodies. Here we propose different
levels of risk based on the results of anti-HLA antibody testing in neat serum
(N) and after sera dilution (DIL) and C1q test in 18 highly sensitized
patients. This group was heterogeneous in terms of anti-HLA antibody titers and
their ability to fix complement. After dilution, 15 out of 18 patients (83.3%)
showed a reduction of positive bead counts whereas 4 patients showed a prozone
effect and complement fixation was demonstrated. The high dilution of sera and
ascertaining the complement fixation allow the accurate definition of risk
anti-HLA antibody profiles in highly sensitized patients, as demonstrated in 5 of
the sensitized patients who were transplanted.
Reference:
Product link:
No comments:
Post a Comment